e t a l . P D - L 1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol, 2017, 12(2): 208-222. doi: 10.1016/j.jtho.2016.11.2...
安捷伦公司为帕博利珠单抗量身定制的 PD-L1 伴随诊断PD-L1 IHC 22C3 pharmDx 率先获批，因此TPS被推广认可。然而后期进入 PD-L1 检测的其他试剂和平台为了防止知识产权纠纷选用 TC 作为指标名称，比如 FDA 批准VENTANAPD-L1(SP142) assay用于阿替利珠单抗伴随/补充诊断，获批的阈值为TC ≥ 50% 或 IC ≥ 10%。
21. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint pd-l1 ihc assay comparison project. J Thorac Oncol. 2017;12(2):208-222. 22. Ye M, ...
(ateolizumab)伴随诊断免疫组化检测试剂为VENTANA PD-L1 (SP142) Assay,应用兔单抗SP142和OptiView DAB IHC检测试剂盒,在VENTANA BenchMark ULTRA染色平台对尿路上皮癌的石蜡切片进行PD-L1表达的分析。PD-L1表达状况定义为任何强度PD-L1+的浸润免疫细胞(IC)所占据的肿瘤细胞面积的百分比,肿瘤细胞上的PD-L1表达不...
21. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint pd-l1 ihc assay comparison project. J Thorac Oncol. 2017;12(2):208-222. 22. Ye M, Huang D, Zhang Q, et al. Heterogeneous programmed death-liga...
PD-1/PD-L1免疫治疗患者入排检测服务 免疫治疗中针对EGFR及ALK阴性非小细胞肺癌患者入排检测,熙宁生物|精翰生物NGS和PCR平台有多款产品可以支持,针对HER2阴性胃癌和三阴性乳腺癌患者入排检测,熙宁生物|精翰生物的IHC、FISH和CISH平台也可以很好地满足该检测需求,具体的样本检测周期亦可结合申办方需求进行合理调整。
9 H i r s c h F R , Mc e l h i n n y A , S t a n f o r t h D, e t a l . P D - L 1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol, 2017, 12(2): 208-222. doi: 10.1016...
帕博利珠单抗的厂商默沙东首先开始通过TPS 给人群分层进行临床研究并取得显著的统计学获益。安捷伦公司为帕博利珠单抗量身定制的PD-L1 伴随诊断PD-L1 IHC 22C3 pharmDx 率先获批,因此TPS被推广认可。 然而后期进入PD-L1 检测的其他试剂和平台为了防止知识产权纠纷选用TC 作为指标名称,比如 FDA 批准VENTANAPD-L1(SP142...
We agree with the authors in that the development of unique PD-L1 IHC assay for each available anti-PD-L1/anti PD-1 agent has made it very complex for laboratories to be able to implement and offer these tests. This article is protected by copyright. All rights reserved....
[2] Hirsch FR et al. PD-L1 Immunohistochemistry Assaysfor Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC AssayComparison Project. J Thorac Oncol. 2017 ;12(2):208-222. [3] Tsao MS et al. PD-L1Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Resultsof...